+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market - Global Forecast 2025-2030- Product Image
Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market - Global Forecast 2025-2030- Product Image
Sale

Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6125186
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

As the therapeutic landscape for hepatobiliary disorders continues to evolve, the ursodeoxycholic acid market stands at the forefront of pharmaceutical innovation, offering sophisticated treatment approaches for complex liver and biliary diseases. Stakeholders are witnessing a period marked by advances in formulation technology, dynamic regulatory environments, and strong integration of digital health tools, creating a robust environment for growth and differentiation.

Market Snapshot: Ursodeoxycholic Acid Market Dynamics

The ursodeoxycholic acid market is distinguished by its steady expansion, fueled by increased global incidence of hepatobiliary disorders and the broad adoption of UDCA as a vital pharmaceutical intervention. The sector benefits from a proven clinical track record, with continued innovation in delivery mechanisms and synergistic combination therapy trials. Regulatory approvals vary worldwide, shaping access and adoption pathways across both developed and emerging healthcare systems.

Scope & Segmentation Overview

  • Indication: The market is segmented by cholesterol gallstones and primary biliary cholangitis, with further differentiation by prophylactic versus therapeutic use, and by combination therapy versus monotherapy approaches.
  • Formulation: Product forms include extended-release capsules, standard capsules, ready-to-use oral suspensions, suspensions to be reconstituted, chewable tablets, and standard tablets, each tailored to specific patient populations for adherence and tolerability.
  • Distribution Channel: Channels span private and public hospital pharmacies, manufacturer direct sales through online pharmacies, third-party marketplaces, chain retail pharmacies, and independent retail outlets, reflecting diverse buying and engagement models.
  • End User: Core segments encompass general clinics, specialty clinics, homecare settings (via caregiver or self-administration), and hospitals, including secondary and tertiary institutions, each influencing prescribing trends and support services.
  • Geographical Coverage: Key regional markets include the Americas (with major states in the United States, Canada, Mexico, Brazil, and Argentina), Europe, Middle East & Africa (notably the UK, Germany, France, and leading MEA economies), and Asia-Pacific (notably China, India, Japan, Australia, South Korea, and Southeast Asian nations).
  • Competitive Landscape: Major players driving therapeutic innovation and market leadership include Teva Pharmaceutical Industries Ltd., Viatris Inc., Bausch Health Companies Inc., Dr. Falk Pharma GmbH, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Natco Pharma Ltd., Pharmacosmos A/S, and Abbott Laboratories.

Key Takeaways for Decision-Makers

  • Recent advancements are spearheading the adoption of extended-release and patient-centric dosage forms, enhancing adherence and improved therapeutic results across varied populations.
  • Combination regimens with immunomodulators and antifibrotic agents are under increased investigation, suggesting a trend toward more individualized hepatobiliary care strategies.
  • Distribution is evolving, with online pharmacies and direct-to-patient models gaining traction alongside traditional hospital and retail channels, thereby expanding reach and strengthening supply chain resilience.
  • Stakeholders are responding to shifting regulatory and reimbursement climates by investing in local manufacturing, strategic procurement, and digital patient support infrastructure.
  • Pharmaceutical companies are actively partnering with contract manufacturing organizations and digital solution providers, placing greater emphasis on real-world evidence and telehealth integrations to bolster competitiveness.

Tariff Impact: Adapting to U.S. Policy Shifts

The introduction of revised U.S. tariffs on pharmaceutical ingredients and products in 2025 has altered supply chain structures for ursodeoxycholic acid. Manufacturers are navigating increased production costs, realignment of sourcing strategies, and contract renegotiations throughout domestic and international channels. Hospital pharmacies are pivoting toward local partnerships, while retail and online platforms are adjusting pricing approaches to balance affordability and profitability. Enhanced inventory management and customs expertise have become critical, with ripple effects across procurement cycles and clinical trial management.

Methodology & Data Sources

This report is grounded in rigorous secondary research of peer-reviewed journals, regulatory literature, clinical trial databases, and proprietary industry resources. Primary research included structured interviews with hepatology experts, commercial leaders, and supply chain professionals, supplemented by comprehensive data triangulation and expert validation. Analytical frameworks ensured reliability and minimized bias throughout the process.

Why This Report Matters

  • Provides actionable intelligence for optimizing product portfolios, supply chain strategies, and market entry or expansion plans in the ursodeoxycholic acid sector.
  • Supports evidence-based decision making with insights into regional dynamics, regulatory and tariff implications, and emerging technological advances.

Conclusion

The ursodeoxycholic acid market is undergoing substantial transformation, with innovation in formulations, partnerships, and delivery channels redefining standards of care. Senior executives and market leaders can leverage this report to navigate complexity, capitalize on growth opportunities, and drive superior outcomes in hepatobiliary disease management.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of ursodeoxycholic acid combination therapies with novel bile acid modulators for enhanced cholestatic liver disease management
5.2. Development of targeted drug delivery systems for ursodeoxycholic acid to improve biliary absorption and reduce dosage frequency
5.3. Emergence of generic ursodeoxycholic acid formulations driving competitive pricing and wider access in emerging markets
5.4. Expanded clinical indications of ursodeoxycholic acid for nonalcoholic steatohepatitis and primary biliary cholangitis in late-stage trials
5.5. Regulatory pathways and patent expirations influencing market exclusivity durations for ursodeoxycholic acid manufacturers
5.6. Adoption of real-world evidence from electronic health records to optimize ursodeoxycholic acid treatment protocols in cholestatic conditions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by Indication
8.1. Introduction
8.2. Cholesterol Gallstones
8.2.1. Prophylactic Use
8.2.2. Therapeutic Use
8.3. Primary Biliary Cholangitis
8.3.1. Combination Therapy
8.3.2. Monotherapy
9. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by Formulation
9.1. Introduction
9.2. Capsules
9.2.1. Extended Release Capsules
9.2.2. Standard Capsules
9.3. Oral Suspension
9.3.1. Ready to Use
9.3.2. To Be Reconstituted
9.4. Tablets
9.4.1. Chewable Tablets
9.4.2. Standard Tablets
10. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Private Hospital Pharmacies
10.2.2. Public Hospital Pharmacies
10.3. Online Pharmacies
10.3.1. Manufacturer Direct Sales
10.3.2. Third Party Marketplaces
10.4. Retail Pharmacies
10.4.1. Chain Retail Pharmacies
10.4.2. Independent Pharmacies
11. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. General Clinics
11.2.2. Specialty Clinics
11.3. Homecare Settings
11.3.1. Caregiver Administration
11.3.2. Self Administration
11.4. Hospitals
11.4.1. Secondary Hospitals
11.4.2. Tertiary Hospitals
12. Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Teva Pharmaceutical Industries Ltd.
15.3.2. Viatris Inc.
15.3.3. Bausch Health Companies Inc.
15.3.4. Dr. Falk Pharma GmbH
15.3.5. Sun Pharmaceutical Industries Ltd.
15.3.6. Cipla Ltd.
15.3.7. Glenmark Pharmaceuticals Ltd.
15.3.8. Natco Pharma Ltd.
15.3.9. Pharmacosmos a/S
15.3.10. Abbott Laboratories
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET: RESEARCHAI
FIGURE 24. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET: RESEARCHSTATISTICS
FIGURE 25. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET: RESEARCHCONTACTS
FIGURE 26. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PROPHYLACTIC USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PROPHYLACTIC USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY EXTENDED RELEASE CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY EXTENDED RELEASE CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STANDARD CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STANDARD CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY READY TO USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY READY TO USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TO BE RECONSTITUTED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TO BE RECONSTITUTED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STANDARD TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STANDARD TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY MANUFACTURER DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY MANUFACTURER DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHAIN RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHAIN RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 169. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2018-2024 (USD MILLION)
TABLE 172. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2025-2030 (USD MILLION)
TABLE 173. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2018-2024 (USD MILLION)
TABLE 174. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2025-2030 (USD MILLION)
TABLE 175. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 176. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 177. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 178. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 179. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 180. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 181. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 182. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 183. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 186. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 187. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 188. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 189. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 190. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 191. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 194. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 195. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 196. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 197. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 198. CANADA URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2018-2024 (USD MILLION)
TABLE 202. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2025-2030 (USD MILLION)
TABLE 203. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2025-2030 (USD MILLION)
TABLE 205. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 206. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 207. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 208. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 209. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 210. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 211. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 212. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 213. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 216. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 217. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 218. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 219. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 220. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 221. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 228. MEXICO URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CHOLESTEROL GALLSTONES, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY PRIMARY BILIARY CHOLANGITIS, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL URSODEOXYCHOLIC ACID DRUGS FOR HEPATOBILIARY DISEASES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Bausch Health Companies Inc.
  • Dr. Falk Pharma GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Natco Pharma Ltd.
  • Pharmacosmos A/S
  • Abbott Laboratories

Related Topics

Related Reports

Ursodeoxycholic Acid Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application - Product Image

Ursodeoxycholic Acid Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application

  • Report
  • 94 Pages
  • Global
From
Ursodeoxycholic Acid - Global Strategic Business Report - Product Image

Ursodeoxycholic Acid - Global Strategic Business Report

  • Report
  • 468 Pages
  • Global
From
Ursodeoxycholic Acid Market - Global Forecast 2025-2030 - Product Image

Ursodeoxycholic Acid Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Ursodeoxycholic Acid Capsules Market - Global Forecast to 2030 - Product Image

Ursodeoxycholic Acid Capsules Market - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Ursodeoxycholic Acid Global Market Report 2025 - Product Image

Ursodeoxycholic Acid Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.